**Table 2.** Histomorphometric criteria for the repair of a bone defect within 2-4 weeks after construct implantation (Me[25;75]).

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | Area of mandibular defect | | | | | | | | | | |  | | | | | |
| Experiment period | | | | Experience  CH-SA-HA1 | | | | | | Control  Healing under a blood clot1 | | | | | Defect periphery1  Control + experience | | | | | |
| Numerical density of inflammatory infiltrate (unit/0.043 mm2) | | | | | | | | | | | | | | | | | | | | | | | |
| 2 weeks1 | | | | 26,8[24,2;28,5] | | | | 31,5[28,8;33,7]\*\* | | | | | 13,2[11,3;14,4]\*\* | | | | |
| 3 weeks1 | | | | 17,2[15,8;19,9] | | | 17,5[15,7;22,6] | | | | | 6,2[5,7;7,1]\*\* | | | | | |
| Volumetric density of bone tissue (BV %) | | | | | | | | | | | | | | | | | | | | | | | |
| 2 weeks1 | | | 30,0[28,8;31,0] | | 28,3[25,8;29,9]\*\* | | | | | | | | 65,0[63,8;66,5]\*\* | | |
| 3 weeks1 | | | 41,3[39,6;43,6] | | 38,6[36,1;40,2]\*\* | | | | | | | | 67,8[67,0;69,3]\*\* | | |
| 4 weeks1 | | | 62,9[60,7;66,8] | | 60,9[58,0;62,0]\*\* | | | | | | | | 66,5[64,3;68,1]\*\* | | |
| Trabeculae thickness (TT mm) | | | | | | | | | | | | | | | | | | | | | | | |
| 2 weeks1 0,12[0,11;0,13] 0,11[0,10;0,12]\* 0,16[0,16;0,17]\*\* | | | | | | | | | | | | | | | | | | | | | | | |
| 3 weeks1 0,13[0,11;0,14] 0,12[0,12;0,13]\* 0,15[0,14;0,16]\*\* | | | | | | | | | | | | | | | | | | | | | | | |
| 4 weeks1 0,16[0,15;0,17] 0,14[0,13;0,15]\* 0,16[0,15;0,17]\*\* | | | | | | | | | | | | | | | | | | | | | | | |
| Intertrabecular spaces (ITS mm) | | | | | | | | | | | | | | | | | | | | | |
| 2 weeks1 0,37[0,36;0,37] 0,39[0,38;0,40]\*\* 0,22[0,22;0,24]\*\* | | | | | | | | | | | | | | | | | | | | | |
| 3 weeks1 0,29[0,28;0,30] 0,30[0,29;0,31]\*\* 0,24[0,23;0,25]\*\* | | | | | | | | | | | | | | | | | | | | | |
| 4 weeks1 0,21[0,21;0,22] 0,22[0,21;0,22]\*\* 0,21[0,20;0,22] | | | | | | | | | | | | | | | | | | | | | |
| Osteoblastic surface (OS %) | | | | | | | | | | | | | | | | | | | | | | | |
| 2 weeks1 | | 58,9[57,0;60,2] | | | 49,9[49,5;50,4]\*\* | | | | | | | | 13,1[12,4;13,7]\*\* | | | | | |
| 3 weeks1 | | 50,8[49,0;53,1] | | | 42,0[39,6;43,9]\*\* | | | | | | | | 9,1[8,4;9,8]\*\* | | | | | |
| 4 weeks1 | | 38,9[37,1;40,1] | | | | | | | 36,0[34,7;37,0]\*\* | | | | | 7,2[6,3;7,8]\*\* | | | | | |
| Erosed bone surface (ES %) | | | | | | | | | | | | | | | | | | | | | |
| 2 weeks1 | 3,5[3,3;3,6] | | | | | | | 3,9[3,7;3,9]\*\* | | | | | 6,1[5,5;6,9]\*\* | | | | |
| 3 weeks1 | 5,9[5,6;6,1] | | | | | | | 6,4[6,1;6,6]\*\* | | | | | 2,9[2,7;3,0]\*\* | | | | |
| 4 weeks1 | 9,9[9,7;10,0] | | | | | | | 10,7[10,5;11,1]\*\* | | | | | 1,3[1,2;1,4]\*\* | | | | |

\* Differences are reliable with the CH-SA-HA group (p<0.05)

\*\*Differences are reliable when compared with the CH-SA-HA group (p<0.01)

1Significant differences in multiple comparisons ANOVA (p<0.001)